EUVIMEDEUVIMED entdecken
Crossref

Trabectedin in the treatment of soft tissue sarcoma: Real‐world data on effectiveness, safety, and financial implications from a European comprehensive cancer center

Jean-Stéphane Giraud iD, Sarah Watson iD, Alexandre Acramel, Valérie Laurence, Dimitri Tzanis, Sylvie Bonvalot, Sophie El Zein, Nayla Nicolas, Cyrille Cros, Romain Desmaris, Clément Bonnet

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Jean-Stéphane Giraud und 10 weiteren Autor:innen. Beteiligte Einrichtung: Département de Pharmacie, Institut Curie, PSL Research University, Paris, France. Hauptthemen laut MEDLINE: Trabectedin, Sarcoma, Antineoplastic Agents, Alkylating. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Soft‐tissue sarcomas (STS) comprise over 150 histological subtypes, with advanced cases showing poor prognosis (5‐year survival

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrabectedinSarcomaAntineoplastic Agents, AlkylatingHumansFemaleRetrospective StudiesMiddle AgedAgedMaleAdultLeiomyosarcomaCancer Care FacilitiesFranceAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

drug‐related side effects and adverse eventshealth care economics and organizationssarcomatrabectedintreatment outcome

Substanzen

TrabectedinAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Département de Pharmacie, Institut Curie, PSL Research University, Paris, France.
  • Institut Cochin, Inserm U1016, CNRS UMR8104, Université Paris Cité, CARPEM, Paris, France.
  • Department d'Oncologie Médicale, Institut Curie, PSL Research University, Paris, France.
  • Université Paris Cité, CiTCoM, CNRS UMR 8038, Inserm U1268, Paris, France.
  • Department of Surgical Oncology, Institut Curie, PSL Research University, Paris, France.
  • Département de Médecine Diagnostique et Théranostique, Institut Curie, PSL Research University, Paris, France.

ORCID-Profile: Jean-Stéphane Giraud, Sarah Watson

Zitieren

APA

Giraud, J. S., Watson, S., Acramel, A., Laurence, V., Tzanis, D., Bonvalot, S., El Zein, S., Nicolas, N., Cros, C., Desmaris, R., & Bonnet, C. (2026). Trabectedin in the treatment of soft tissue sarcoma: Real‐world data on effectiveness, safety, and financial implications from a European comprehensive cancer center. International Journal of Cancer. https://doi.org/10.1002/ijc.70403

Vancouver

Giraud JS, Watson S, Acramel A, Laurence V, Tzanis D, Bonvalot S, et al. Trabectedin in the treatment of soft tissue sarcoma: Real‐world data on effectiveness, safety, and financial implications from a European comprehensive cancer center. International Journal of Cancer. 2026. doi:10.1002/ijc.70403

BibTeX
@article{Giraud2026,
  author = {Giraud, Jean-Stéphane and Watson, Sarah and Acramel, Alexandre and Laurence, Valérie and Tzanis, Dimitri and Bonvalot, Sylvie and El Zein, Sophie and Nicolas, Nayla and Cros, Cyrille and Desmaris, Romain and Bonnet, Clément},
  title = {Trabectedin in the treatment of soft tissue sarcoma: Real‐world data on effectiveness, safety, and financial implications from a European comprehensive cancer center},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70403}
}
Kostenlos starten →